Stock CLRB CELLECTAR BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Real-time Estimate Cboe BZX
Other stock markets
 03:01:10 2024-05-06 pm EDT 		5-day change 1st Jan Change
3.39 USD -0.88% Intraday chart for Cellectar Biosciences, Inc. +8.71% +21.66%
Mar. 28 Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating MT
Mar. 28 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating MT

Evolution of the average Target Price on Cellectar Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5968927bcb9.yjbIy7baUGDQcCpMiVcwgQc3TSi4lzMr7cNdtZkn8mc.hUyxpdeeBiGpXRwp42Jq8WB8J2Lp21ZIp7Mo7eBKxgWkWbmZ7J40LJo4WQ~033ac759c0e77e6a8d21eb9559fd8ef7

Analyst Recommendations on Cellectar Biosciences, Inc.

Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating MT
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating MT
Investors lower their expectations Our Logo
Oppenheimer Cuts Cellectar Biosciences Price Target to $8 From $10, Maintains Outperform Rating MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $47 From $5.50, Maintains Outperform Rating MT
Maxim Group Adjusts Cellectar Biosciences Price Target to $2 From $3, Maintains Buy Rating MT
Cellectar Biosciences : Says Data From Trial Show 16.7% Complete Response Rate in Rare Blood Cancer Patients; Shares Down MT
CELLECTAR BIOSCIENCES : Oppenheimer Adjusts Cellectar Biosciences' Price Target to $5.50 From $5, Maintains Outperform Rating MT
Cellectar Biosciences, Inc. Reports Positive Top-Line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of Clr 131 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.42 USD
Average target price
15 USD
Spread / Average Target
+338.60%
High Price Target
28 USD
Spread / Highest target
+718.71%
Low Price Target
7 USD
Spread / Lowest Target
+104.68%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cellectar Biosciences, Inc.

Roth MKM
Oppenheimer
HC Wainwright
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CLRB Stock
  4. Consensus Cellectar Biosciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW